Does CorMedix (CRMD) Have the Potential to Rally 68.74% as Wall Street Analysts Expect?Zacks Investment Research • 12/09/25
CorMedix (CRMD) Upgraded to Strong Buy: Here's What You Should KnowZacks Investment Research • 12/08/25
CorMedix: Raised Guidance, NOL Confidence, And Rezzayo Optionality Justify A Hold RatingSeeking Alpha • 11/14/25
Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate UpdatePRNewsWire • 11/12/25
CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 GuidanceGlobeNewsWire • 11/12/25
Wall Street Analysts Predict an 80.58% Upside in CorMedix (CRMD): Here's What You Should KnowZacks Investment Research • 11/10/25
All You Need to Know About CorMedix (CRMD) Rating Upgrade to Strong BuyZacks Investment Research • 11/04/25
CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025GlobeNewsWire • 10/31/25
4 High-Earnings Yield Value Picks Ahead of Potential Fed Rate CutZacks Investment Research • 10/29/25
CorMedix: Strong Buy After Strong Developments And A Strategy Before EarningsSeeking Alpha • 10/24/25
CorMedix Inc. Receives Innovative Technology Designation From Vizient for DefenCathGlobeNewsWire • 10/23/25
Halper Sadeh LLC Encourages CorMedix Inc. Shareholders to Contact the Firm to Discuss Their RightsBusiness Wire • 10/22/25
Wall Street Analysts See a 68.59% Upside in CorMedix (CRMD): Can the Stock Really Move This High?Zacks Investment Research • 10/21/25
CorMedix (CRMD) Surges 19.5%: Is This an Indication of Further Gains?Zacks Investment Research • 10/21/25
How Will DefenCath Aid CRMD's Top Line in the Upcoming Q3 Results?Zacks Investment Research • 10/20/25
CorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue GuidanceGlobeNewsWire • 10/20/25